Immunotherapy before surgery shrinks lung tumors in Early-Stage trial
NCT ID NCT03158129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) or immunotherapy plus chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if these treatments could shrink or eliminate the tumor before surgical removal. The trial enrolled 101 participants and measured how many had a major or complete response in the tumor tissue after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I LUNG NON-SMALL CELL CANCER AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung cancer combo after surgery fails to extend life
- New cocktail for tough lung cancer shows promise in small trial
- Could PET scans guide radiation to better fight lung cancer?
- New combo aims to control lung cancer that returns after standard therapy
- Experimental drug combo aims to outsmart resistant lung cancer
- Massive lung cancer study aims to match patients with targeted therapies